On 20 March, members of the Multi-MeMo Advisory Board (AB) gathered for an online meeting. Multi-MeMo (“Shorter- and longer-term mechanisms of multimodal interventions to prevent dementia”) is a European funded project that focuses on brain health in older people, overall, and tailored, multidomain (i.e., targeting simultaneously multiple risk factors) interventions for the risk-reduction of cognitive impairment and dementia, in particular. The meeting was attended by five AB members, including members of the public with and without cognitive impairment from five European countries. It was divided into two main parts. The first part featured an informative presentation by Dr. Francesca Mangialasche from Karolinska Institutet (Sweden). Her talk, titled “The European Regulatory Path of Disease Modifying Drugs – What is Happening in Europe?” provided insightful updates on the latest developments in disease-modifying drug treatments.
Following her presentation, participants were invited to ask questions, creating an interactive discussion. In the second part of the meeting, a consultation session allowed AB members to share their views and concerns regarding the impact of these developments and their possible impact on the general population in Europe and preventive programmes (e.g., FINGER). AB members provided valuable feedback, which will help guide both current and future research within the Multi-MeMo consortium. The overall meeting was facilitated by Sarah Campill (Alzheimer Europe), who was joined by Cindy Birck, Ana Diaz (Alzheimer Europe), Francesca Mangialasche (Karolinska Institutet) and Mariagnese Barbera (University of Eastern Finland).
For further information about Multi-MeMo, please visit the project’s website: https://www.multi-memo.eu/
Multi-MeMo is an EU Joint Programme – Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND – www.jpnd.eu: Finland, Research Council of Finland; Germany, Federal Ministry of Education and Research; Luxembourg, National Research Fund; Netherlands, The Netherlands Organisation for Health Research and Development; Slovakia, Ministry of Education, Science, Research and Sport of the Slovak Republic; Spain, National Institute of Health Carlos III.